| Condition | Prevalence in Specific Samples |
|---|---|
| Autoimmune diseases | |
| Polymorphic reticulosis | 7/34 (21%)94 |
| Endocrine diseases | |
| Diabetes mellitus | 14/22 (64%) with nocturnal hypoglycemia95 |
| Obesity, severe in residential treatment of obesity | 20/152 (13%) men; 47/234 (20%) women96 |
| Infectious diseases | |
| Adenovirus, immunocompromised | 4/15 (27%)97 |
| Endocarditis, Cardiobacterium hominis | 14/61 (24%)98 |
| HIV, acute | 5/58 (9%) of p24 Ag+/HIV−66 |
| 7/20 (35%)99 | |
| 59/328 (18%)67 | |
| 88/151 (58%)100 | |
| HIV, chronic | 18/22 (82%)68 |
| 39/328 (12%)67 | |
| 19/49 (31%)101 | |
| 126/899 (14%)73 | |
| 7/34 (21%)91 | |
| 40/168 (24%)102 | |
| 26/100 (26%)103 | |
| 62/109 (57%)104 | |
| 144/205 (70%) (average once/week)105 | |
| 18/176 (10%) with no AIDS-defining illnesses50 | |
| HIV+, IV drug users | 33/124 (27%)69 |
| HIV+, generalized lymphadenopathy | 12/38 (32%)71 |
| HIV+, Mycobacterium avium complex | 36/91 (40%)106 |
| 27/31 (87%)74 | |
| 21/25 (84%)75 | |
| 18/24 (75%)76 | |
| 67/187 (36%)77 | |
| HIV+, Pneumocystis carinii pneumonia | 46/99 (46%)107 |
| HIV+, pneumonia, bacterial | 22/94 (23%)107 |
| HIV+, tuberculosis | 66/85 (78%)*108 |
| 306/899 (34%)73 | |
| With pleural effusion 54/65 (83%)109 | |
| 19/36 (53%)107 | |
| 24/48 (50%)72 | |
| Pneumonia, bacterial | 104/329 (32%)110 |
| Tuberculosis | 22/40 (55%)111 |
| Young adults 179/419 (43%), older adults 15/45 (33%)112 | |
| Young adults 34/73 (46%), older adults 17/72 (24%)113 | |
| Young adults 48/88 (55%), older adults 9/50 (18%)114 | |
| Young adults 14/29 (48%)115 | |
| Older adults 2/35 (6%)115 | |
| 12/17 (71%)110 | |
| 24/98 (25%) TB patients presenting with lymphadenopathy88 | |
| 148/313 (48%) of TB outpatients116 | |
| 11/31 (35%) of TB outpatients72 | |
| Tuberculosis, Beijing type | Young adults 14/29 (48%) |
| Older adults 2/35 (6%)115 | |
| Tuberculosis | |
| Beijing | 308/880 (35%) |
| Non-Beijing type | 378/880 (43%)117 |
| Beijing | 2/21 (10%) |
| Non-Beijing type | 7/20 (35%)118 |
| Tuberculosis, extrapulmonary | 99/209 (48%) of patients with abdominal TB119 |
| Medications | 28/54 (54%) with extrapulmonary TB116 |
| Oblimersen sodium | 7/40 (18%)120 |
| Tacatuzumab | 2/12 (17%)121 |
| Miscellaneous diseases | |
| Inflammatory pseudotumor | 2/25 (8%)122 |
| Neoplastic and hematologic diseases | |
| Acute lymphocytic leukemia | 8/10 (80%)123 |
| Acute myelocytic leukemia | 8/22 (36%)123 |
| Lymphoma | 14/85 (17%) of those presenting with lymphadenopathy88 |
| 7/50 (14%) with generalized lymphadenopathy71 | |
| 3/10 (30%) lymphoma primary in liver124 | |
| 4/14 (29%) with EBV Hodgkin disease87 | |
| 5/12 (42%) with pancreatic lymphoma87 | |
| Metastatic, mixed | 5/17 (29%) of those presenting with lymphadenopathy88 |
| Mesothelioma, peritoneal | 3/17 (18%)125 |
| Mixed, terminal | 12/77 (16%) admission to hospice |
| 19/77 (25%) just before death126 | |
| Myelofibrosis | 255/456 (56%)127 |
| 8/22 (36%)128 | |
| 12/56 (21%)129 | |
| Pancreatic cancer | 1/30 (3%)130 |
| Polycythemia vera | 198/405 (49%)127 |
| Prostate cancer, inflammatory | 7/12 (58%)90 |
| Thrombocythemia, essential | 125/304 (41%)127 |
| Pulmonary diseases | |
| Eosinophilic pneumonia | 3/65 (5%)131 |
| Sleep disorders | |
| Obstructive sleep apnea | 65/406 (16%)132 |
| Toxic and metabolic diseases | |
| Silicone breast implants | 22/50 (44%)133 |
↵* Compilation of several case series.
EBV, Epstein-Barr virus; IV, intravenous; TB, tuberculosis.